ClinicalTrials.gg
Active, not recruitingNCT07082777RETELLUpdated Jun 4, 2026

Recovery in Telling Life Stories

An interventional study of Narrative therapy in Schizophrenia Disorders, Personality Disorders and Obsessive - Compulsive Disorder, sponsored by University of Aarhus. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Schizophrenia with a site in Denmark — 10 open to participants now, 12 under way, none of them phase 3. Schizophrenia · Denmark.

Planned enrollment
62nd of 67
20 · median 108
Started
2025
with 4 others
No phase
38 of 79
4 open now
Primary completion
2027-04
later than 6 of 11 live
Registered
73rd of 79
by date
Lead sponsor
8 of 79
University of Aarhus

Among the 79 studies in Schizophrenia with a site in Denmark, this one is the 62nd largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 73rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 79 studies in Schizophrenia with a site in Denmark are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Schizophrenia with a site in Denmark, or all of them as a file.
02

Study summary

This project tests the Recovery In Telling Life Stories (RETELL) intervention, aimed at supporting personal recovery in people with severe mental illness (SMI). While many of those with SMI experience symptom control, their quality of life often remains low due to social loss, negative self-perceptions, and identity-related challenges not addressed by standard treatments. Through a process of narrative repair, the RETELL intervention helps participants explore the personal consequences of mental illness while supporting the enhancement of narratives that strengthen identity and foster well-being. The intervention is delivered across 8-12 sessions and will be assessed for feasibility of both the intervention and study procedures. We will also explore its preliminary impact on recovery, quality of life, symptoms, functioning, self-stigma, and personality, using a multiple single-case A-B-A design. We expect the intervention and study procedures to show acceptable feasibility. We further hypothesize that participants' scores on recovery and well-being will be low at baseline, improve during the intervention, and remain higher after the intervention ends and at 3-month follow-up. This study will provide a foundation for future randomized controlled trials.

Read the detailed description

This project tests the Recovery In Telling Life Stories (RETELL) intervention, an intervention developed to support personal recovery in individuals with severe mental illness (SMI).

Research shows that many people with SMI experience low quality of life even when their symptoms are in remission and functional level, e.g. cognitive remediation. This is not only due to the illness itself but also to the consequences that often accompany it, such as the loss of social and occupational roles and the development of negative self-perceptions. These challenges are only to a limited extent addressed by existing treatments, which typically focus on symptom reduction.

Personal recovery is about living a satisfying and meaningful life despite the potential constraints associated with mental illness. A major barrier to this process can arise when a person develops an understanding of themself (a narrative identity) characterized by shame, low self-esteem, and self-stigmatization. When negative identity conclusions dominate, it can be difficult to experience well-being, meaning in life, or hope for the future.

Despite an increasing focus on personal recovery in mental health care systems globally, evidence-based methods to support the recovery process are limited. In this project, we develop and test the RETELL intervention, designed to support personal recovery by helping participants process the personal consequences of mental illness and identify and cultivate positive identity conclusions and personal strengths. In RETELL, the participants are guided through this process, which we refer to as narrative repair, over a structured sequence of 8-12 sessions. Across these sessions, participants are guided in telling their life story and in constructing preferred and empowering narratives about themselves and their future.

The intervention will be tested in a mixed methods study using a one-arm multiple single-case intervention design with an A-B-A structure. This includes a pre-intervention phase (T1) with four weeks of outcome measurements, an intervention phase (T2) continuing with the same measures every second week, 4 weeks of post-intervention measurements (T3), and 4 weeks of follow-up measurements starting 3 months after intervention completion (T4). Data will be collected in electronic surveys and qualitative interviews. The primary aim is to assess intervention feasibility including potential to improve recovery and quality of life. It is aimed to recruit 20 participants diagnosed with SMI within the timeframe allowed by the study plan.

Feasibility will be assessed in terms of both intervention and study procedure feasibility, as this study will form the basis for larger randomized controlled trials. Intervention feasibility will be evaluated based on treatment dropout, treatment satisfaction and trajectory of self-reported recovery compared to pre-intervention. Feasibility will be indicated by \< 30% dropout, a mean sum score of ≥ 20 on the Client Satisfaction Questionnaire, and increase or stability of self-reported recovery throughout the study period compared to pre-intervention. Study procedure feasibility includes recruitment acceptance rate, questionnaire response rate and study dropout rate. We tentatively propose a ≥ 50% recruitment acceptance rate, ≥ 75% questionnaire response rate and ≤ 25% study dropout rate as indicating acceptable study feasibility.

Secondary outcomes include well-being, domain-specific recovery, overall functioning, symptom levels, and self-stigmatization. In addition, changes from pre- to post-intervention in personality trait scores will be explored. Statistical analyses will include dependent t-tests to examine effect sizes and changes in quantitative outcomes, and these will be interpreted with attention to clinical significance. Finally, interviews about participants' experiences with the intervention will be thematically analyzed to identify perceived helpful elements, potential mechanisms of change and to inform the refinement of the programme theory.

03

Conditions studied

  • Schizophrenia Disorders
  • Personality Disorders
  • Obsessive - Compulsive Disorder
  • Anxiety Disorders
  • Recurrent Depressive Disorder
  • PTSD - Post Traumatic Stress Disorder
  • Hyperkinetic Disorders
  • Eating Disorders
  • Bipolar Disorders
  • Aspergers Syndrome

Keywords

  • personal recovery
  • recovery
  • narrative identity
  • narrative therapy
  • severe mental illness
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between the ages of 18 and 65 years
  • A self-reported principal diagnosis of one or more of the following: schizophrenia (F20), bipolar disorder (F31), personality disorders (F60), obsessive-compulsive disorder (F42), anxiety disorders (F41), recurrent depressive disorder (F33), eating disorders (F50), hyperkinetic disorders (F90), post-traumatic stress disorder (F43.1), Asperger syndrome (F84.5)
  • Not in full recovery (Brief INSPIRE-O \< 50)
  • Danish language proficiency
  • Medication stabilized (i.e., same type and dosage for a minimum of 8 weeks)
  • Ability and willingness to give

Exclusion criteria

Exclusion Criteria:

  • Self-reported diagnosis of mental retardation (F70-79) and/or organic mental disorder (F00-09)
  • Psychiatric symptoms, thoughts of self-harm and/or substance abuse of self-reported severity which are likely to prevent one or all of the following: attendance at scheduled sessions, completion of questionnaires before, during and after the intervention, meaningful engagement in the therapeutic process
  • Psychiatric hospitalization in the past 4 weeks
  • Prior conviction of violent crime
  • Currently homeless
  • Currently in psychotherapy initiated within the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    RETELL

    Narrative therapy to support personal recovery, delivered individually over 8-12 sessions.

    Behavioral: Narrative therapy

Interventions

  • BehavioralNarrative therapy

    The intervention is structured around 4 central tasks focusing on different aspects of narrative repair. Task 1: Introduction to life story exploration and building alliance. Task 2: Explore and process the impact of mental illness on identity, externalizing negative narratives, and making sense of emotional responses such as guilt, grief, or shame. Task 3: Identify positive identity conclusions (e.g., strengths, values, skills) from past or current life experiences, and support their integration into the personal narrative. Task 4: Support the imagining of a realistic and hopeful future narrative, grounded in insights of previous sessions. Tasks 1-4 are addressed in a total of 8-12 sessions, depending on the specific user needs. Sessions will have an app. duration of 45-60 mins and will be delivered by the PI who is a trained therapist and psychologist (MSc. Psych.), receiving ongoing supervision. The intervention manual will be made freely available in relation to study publication.

    Also known as: Recovery in Telling Life Stories (RETELL)

06

What researchers measure

Primary outcomes

  1. Intervention feasibility: Treatment dropout rate

    Treatment dropout is defined as participation in less than three out of the four therapeutic tasks of the intervention. Feasibility will be indicated by a dropout rate \< 30%.

    Time frame: Through intervention phase (T2), between 8-12 weeks

  2. Intervention feasibility: Satisfaction with treatment (quantitative)

    Participant-reported treatment satisfaction using the using the Client Satisfaction Questionnaire (CSQ), a brief, standardized self-report measure designed to assess clients' overall satisfaction with healthcare or psychological services. It consists of 8 items rated on a Likert scale, covering aspects such as service quality, perceived helpfulness, and whether the service met the client's needs. Total score range: 8-32, with higher numbers indicating greater satisfaction. Feasibility will be indicated by a mean score of 20 or above.

    Time frame: Post-intervention (T3)

  3. Intervention feasibility: Change from pre-intervention throughout the intervention to post-intervention and follow-up in personal recovery

    Recovery will be assessed using the Brief INSPIRE-O, consisting of 5 items reflecting five dimensions of personal recovery: connectedness with others, hope and optimism for the future, positive identity, meaning in life, and empowerment, with a score range of 0-100. Feasibility will be indicated by stability or increase throughout the study period compared to pre-intervention.

    Time frame: Pre-intervention (T1), intervention (T2), post-intervention (T3) and follow-up (T4)

Secondary outcomes

  1. Intervention feasibility: Number of participants with treatment-related adverse events

    Self-reported adverse events will be monitored during the intervention phase (T2) by systematic inquiry to hospitalization, thoughts of self-harm and suicide attempts, as well as at follow-up points (T3 and T4) by use of the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure for Adults. Participants will also have the opportunity to anonymously report adverse events to a project staff member.

    Time frame: From the beginning of the intervention (T2) to the final 3-month follow-up (T4)

  2. Intervention feasibility: Satisfaction with the therapeutic alliance

    Participant-reported quality of the therapeutic alliance using the Session Rating Scale (SRS), a visual analogue scale (ranging from 0 to 10) that allows individuals to provide feedback on key aspects of the session, such as the therapeutic alliance and overall experience.

    Time frame: Intervention phase (T2)

  3. Intervention feasibility: Satisfaction with treatment (qualitative)

    Participant-reported treatment satisfaction in qualitative, semi-structured interviews

    Time frame: Post-intervention (T3)

  4. Change from pre-intervention throughout the intervention to post-intervention and follow-up in well-being

    Well-being will be assessed using the 5-item World Health Organization's Well-Being Index (WHO-5), designed to measure subjective well-being. Score range: 0-100.

    Time frame: Pre-intervention (T1), intervention (T2), post-intervention (T3) and follow-up (T4)

  5. Change from pre-intervention to post-intervention and follow-up in domain-specific recovery

    Domain-specific recovery will be assessed using the Recovery Assessment Scale-Domains and Stages (RAS-DS), a self-report measure designed to capture an individual's subjective experience of recovery across multiple life domains. The scale assesses four key domains: Doing Things I Value, Looking Forward, Mastering My Illness, and Connecting and Belonging, each reflecting different aspects of personal recovery. Items are rated on a 4-point Likert scale, ranging from 1 (Untrue) to 4 (Completely true). The total scale score ranges from 38-152, with higher scores indicating greater perceived recovery. The RAS-DS is grounded in a consumer-oriented understanding of recovery and has demonstrated good psychometric properties across various mental health populations.

    Time frame: Pre-intervention (T1), post-intervention (T3) and follow-up (T4)

  6. Change from pre-intervention to post-intervention and follow-up in functioning and disability

    Functioning and disability will be assessed using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) 12-item version, a brief, standardized self-report instrument developed to assess difficulties in daily functioning across the past 30 days. Responses are scored on a 5 point Likert scale: None (0), Mild (1), Moderate (2), Severe (3), and Extreme/Cannot Do (4).

    Time frame: Pre-intervention (T1), post-intervention (T3) and follow-up (T4)

  7. Change from pre-intervention to post-intervention and follow-up in symptomatic status

    Symptomatic status will be assessed using the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure for Adults, a standardized screening tool to assess a broad range of psychiatric symptoms across multiple diagnostic domains. The measure includes 23 items covering 13 symptom domains (e.g., depression, anxiety, psychosis, sleep problems, and substance use), each rated on a 5-point scale from 0 (none) to 4 (severe), reflecting symptom severity over the past two weeks.

    Time frame: Pre-intervention (T1), post-intervention (T3) and follow-up (T4)

  8. Change from pre-intervention to post-intervention and follow-up in self-stigmatization

    Self-stigmatization will be assessed using the 10-item version of the Internalized Stigma of Mental Illness Scale (ISMI), a brief, validated self-report measure used to assess the degree to which individuals internalize negative beliefs and stereotypes about mental illness across the following subscales: Alienation, Discrimination Experience, Social Withdrawal, Stereotype Endorsement, and Stigma Resistance. Responses are a 4-point Likert scale ranging from strongly disagree (1) to strongly agree (4) for a total score range of 10 to 40, with higher scores representing more severe internalized stigmatization.

    Time frame: Pre-intervention (T1), post-intervention (T3) and follow-up (T4)

  9. Change from pre-intervention to follow-up in Big 5 personality traits

    Big 5 personality traits will be assessed using the Big Five Inventory-2-S (BFI-2-S), a 30-item short form of the BFI-2 designed to measure the five broad personality domains: Extraversion, Agreeableness, Conscientiousness Neuroticism, and Openness to Experience. Each trait is assessed with 6 items rated on a 5-point Likert scale ranging from 1 (disagree strongly) to 5 (agree strongly).

    Time frame: Pre-intervention (T1) and post-intervention (T3)

  10. Study procedure feasibility: Acceptance rate

    The proportion of participants enrolled from the number of individuals who received oral and written information about the study from the study coordinator, and were found to be eligble during screening.

    Time frame: Study recruitment phase, approximately 15 months

  11. Study procedure feasibility: Questionnaire response rate

    The average percentage of questionnaires completed within each batch (e.g., T1) and overall (T1-T4).

    Time frame: Throughout study completion, an average of approximately 35 weeks.

  12. Study procedure feasibility: Study drop-out rate

    Rate of nonresponse to any complete batch of questionnaires during intervention phase, at postintervention or follow-up

    Time frame: Throughout study completion, an average of approximately 35 weeks.

07

Study locations

1 site
  • Aarhus Univerity
    Aarhus C, 8000, Denmark
08

References and documents

Publications

  • Thomsen, D. K., et al. (2023). Storying Mental Illness and Personal Recovery. Cambridge, Cambridge University Press.

Individual participant data

Plan to share: No — Individual participant data from this study will not be shared due to their highly sensitive nature. The data include detailed narratives and information related to mental health, which pose a significant risk of re-identification-even if direct identifiers are removed. Given the ethical obligation to safeguard participants' privacy and the strict requirements of data protection regulations (e.g., GDPR), we have determined that sharing IPD would not be compatible with the informed consent provided by participants or with responsible research conduct. Therefore, only aggregate findings will be shared upon request, and only for research purposes.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 20 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 24, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07082777
Responsible party
Dinne Christensen (Principal Investigator ,Postdoc, PhD, University of Aarhus) — Principal investigator
First posted
Jul 24, 2025
Start date
Jul 21, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Dorthe K. Thomsen, PhD
study chair · University of Aarhus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion